Wyeth ships the drug to doctors, and a percentage of sales are given to MedImmune.
MedImmune shares jumped 18% on April 23, 2007, the day the deal was announced.
Both AstraZeneca and MedImmune have been criticized for the number of medicines they have in late-stage testing.
We're talking about tech stocks like Ebay, medical stocks like MedImmune and even old-line retailers like Walgreen.
Because of the difficulty of estimating how many doses were sold, returned, or discounted, MedImmune couldn't book sales.
At first, many analysts expected that the main constraint on sales would be how many doses MedImmune could make.
One big Invesco holding is MedImmune, which is developing a new vaccine that could help protect against cervical cancer.
Both Glaxo and Merck will pay a royalty to MedImmune (nasdaq: MEDI - news - people ).
Biotech MedImmune will get a royalty from the sale of both vaccines.
We're talking about tech stocks like Ebay and medical stocks like MedImmune.
This discovery inspired HPV vaccine programs at such drug giants as Merck and small biotechs as MedImmune in Gaithersburg, Maryland, which supplies the GlaxoSmithKline vaccine.
If it can work some of that marketing magic on MedImmune's products, AstraZeneca might be able to make this multibillion-dollar bet pay off.
She's more convinced by ID Biomedical's data than the data out of Medimmune so she's betting that the smaller company will eventually triumph.
Wyeth and MedImmune may have to relaunch the product from scratch.
But an early-stage pipeline of cancer drugs could be what sold Astra on paying 53% more than MedImmune was worth before news of an impending sale leaked.
In fiscal 2003 MedImmune recorded no sales-related revenue for the vaccine, which is co-marketed with drug giant Wyeth (nyse: WYE - news - people ).
The all-cash offer for MedImmune gives AstraZeneca the rights to Synagis, a preventive for respiratory infections in premature infants, and a follow-up drug that is still in development.
Goldman advised MedImmune and Advanced Medical Optics on the deals.
Goldstein is also waiting on the approval of FluMist, an inhalable flu vaccine the company is co-developing with MedImmune (nasdaq: MEDI - news - people ).
But even during one of the worst influenza seasons in memory, MedImmune and Wyeth may have sold only 800, 000 doses, analysts say, compared to the 4 million in some earlier forecasts.
MedImmune (nasdaq: MEDI - news - people ), a biotech that sells a flu vaccine called FluMist that is given as a nose spray, can probably provide less than 2 million doses.
应用推荐